Krupi Parmar

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Manjunath Krishnappa, Kishor Patil, Krupi Parmar et al. · Cardiovascular Diabetology · 2020 · 46 citations · Full text

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Kevinkumar Kansagra, Rajendrakumar H. Jani, Nuggehally R. Srinivas et al. · Clinical Pharmacokinetics · 2017 · 38 citations · Full text

Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

Ashu Rastogi, Richard L. Dunbar, Hemant Thacker et al. · Acta Diabetologica · 2020 · 16 citations

Metabolic Syndrome, Cardiovascular Disease, Medicine +8

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Maulik Patel, Kevinkumar Kansagra, Devang Parikh et al. · Clinical Drug Investigation · 2017 · 10 citations

Nutrition, Pharmacological Study, Medicine +7